Hertraz 150 (Trastuzumab Vials) 150mg

Trastuzumab works by binding to the HER2 receptor on cancer cells, inhibiting the signalling pathways that promote cell growth and division. It also mediates antibody-dependent cell-mediated cytotoxicity (ADCC), which helps the immune system target and destroy HER2-overexpressing cancer cells.

The dosage of Hertraz 150 is determined by a healthcare professional based on the patient's condition, body weight, and response to treatment. The prescriber will set the appropriate dosing schedule, which may vary depending on the specific indication and treatment regimen.

Hertraz 150 is not recommended for use in pregnant women due to insufficient safety and efficacy data. Breastfeeding should be avoided during Trastuzumab therapy to prevent potential harm to the infant.

To order Hertraz 150 from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will reply with pricing, availability, shipping (including cold-chain where relevant), and the necessary import paperwork.

Hertraz 150 is a monoclonal antibody that specifically targets the HER2 receptor. It is similar to other HER2-targeted therapies in its mechanism of action but may have different efficacy and safety profiles. The choice of therapy depends on the patient's specific condition, treatment history, and response to previous therapies.

Hertraz 150 should be stored at 2-8°C, refrigerated, and protected from light. It should not be frozen or shaken. The reconstituted solution is stable for 28 days when stored refrigerated and should be discarded after this period. The drug solution for infusion diluted in 0.9% Sodium Chloride for Injection may be stored at 2-8°C for up to 24 hours prior to use.

Hertraz 150 is administered via intravenous infusion by a healthcare professional. The infusion should be given slowly, and the patient should be monitored for any infusion-related reactions. The specific administration schedule and duration will be determined by the prescribing healthcare professional.

The most serious risks associated with Hertraz 150 include cardiac dysfunction, infusion-related reactions, haematotoxicity (particularly neutropenia), infections, and pulmonary adverse reactions. Patients should be closely monitored for these risks during treatment.

Hertraz 150 should not be used in children below 18 years of age, pregnant women, and those with a known hypersensitivity to Trastuzumab or any of its components. It should be used with caution in patients with pre-existing cardiac conditions and those who have received prior anthracycline or taxane therapy.